Icon Plc (NASDAQ:ICLR) – Jefferies Group increased their Q2 2018 EPS estimates for shares of Icon in a report released on Thursday. Jefferies Group analyst D. Windley now anticipates that the medical research company will post earnings per share of $1.48 for the quarter, up from their previous forecast of $1.47. Jefferies Group also issued estimates for Icon’s Q3 2018 earnings at $1.58 EPS, FY2018 earnings at $6.08 EPS and FY2019 earnings at $6.74 EPS.
Icon (NASDAQ:ICLR) last posted its earnings results on Thursday, February 15th. The medical research company reported $1.43 EPS for the quarter, topping analysts’ consensus estimates of $1.41 by $0.02. The firm had revenue of $455.10 million during the quarter, compared to analysts’ expectations of $455.66 million. Icon had a net margin of 16.01% and a return on equity of 28.60%. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.33 earnings per share.
A number of other research analysts have also recently commented on the stock. Zacks Investment Research cut shares of Icon from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. Barclays increased their target price on shares of Icon from $108.00 to $120.00 and gave the stock an “equal weight” rating in a report on Friday, October 27th. ValuEngine raised shares of Icon from a “hold” rating to a “buy” rating in a report on Sunday, December 31st. KeyCorp reissued an “overweight” rating and issued a $125.00 target price (up previously from $115.00) on shares of Icon in a report on Monday, November 13th. They noted that the move was a valuation call. Finally, Evercore ISI began coverage on shares of Icon in a report on Thursday, January 18th. They issued an “outperform” rating and a $126.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $126.00.
Icon (NASDAQ ICLR) opened at $115.06 on Monday. The company has a market cap of $6,228.02, a PE ratio of 22.43, a PEG ratio of 1.62 and a beta of 0.48. The company has a quick ratio of 1.90, a current ratio of 1.90 and a debt-to-equity ratio of 0.31. Icon has a fifty-two week low of $76.46 and a fifty-two week high of $124.48.
A number of hedge funds and other institutional investors have recently modified their holdings of ICLR. Cubist Systematic Strategies LLC raised its holdings in Icon by 11.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,844 shares of the medical research company’s stock worth $474,000 after purchasing an additional 481 shares during the last quarter. Aperio Group LLC raised its holdings in Icon by 4.6% during the 4th quarter. Aperio Group LLC now owns 15,640 shares of the medical research company’s stock worth $1,754,000 after purchasing an additional 682 shares during the last quarter. GW&K Investment Management LLC raised its holdings in Icon by 6.5% during the 4th quarter. GW&K Investment Management LLC now owns 11,496 shares of the medical research company’s stock worth $1,289,000 after purchasing an additional 700 shares during the last quarter. Stifel Financial Corp raised its holdings in Icon by 2.1% during the 3rd quarter. Stifel Financial Corp now owns 36,545 shares of the medical research company’s stock worth $4,160,000 after purchasing an additional 763 shares during the last quarter. Finally, Sentry Investment Management LLC raised its holdings in Icon by 2.1% during the 4th quarter. Sentry Investment Management LLC now owns 37,807 shares of the medical research company’s stock worth $4,240,000 after purchasing an additional 763 shares during the last quarter. Institutional investors and hedge funds own 89.18% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Q2 2018 EPS Estimates for Icon Plc Boosted by Analyst (ICLR)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/21/q2-2018-eps-estimates-for-icon-plc-boosted-by-analyst-iclr.html.
Icon Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.